The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8+ T-cell responses: The immunological consequences of the biodistribution profile

A prerequisite for vaccine-mediated induction of CD8+ T-cell responses is the targeting of dendritic cell (DC) subsets specifically capable of cross-presenting antigen epitopes to CD8+ T cells. Administration of a number of cationic adjuvants via the intraperitoneal (i.p.) route has been shown to result in strong CD8+ T-cell responses, whereas immunization via e.g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak CD8+ T-cell responses. The hypothesis for this is that self-drainage of the adjuvant/antigen to the lymphoid organs, which takes place upon i.p. immunization, is required for the subsequent activation of cross-presenting lymphoid organ-resident CD8α+ DCs. In contrast, s.c. or i.m. immunization usually results in the formation of a depot at the site of injection (SOI), which hinders the self-drainage and targeting of the vaccine to cross-presenting CD8α+ DCs. We investigated this hypothesis by correlating the biodistribution pattern and the adjuvanticity of the strong CD8+ T-cell inducing liposomal cationic adjuvant formulation 09 (CAF09), which is composed of dimethyldioctadecylammonium bromide/monomycoloyl glycerol liposomes with polyinosinic:polycytidylic acid electrostatically adsorbed to the surface. Biodistribution studies with radiolabeled CAF09 and a surface-adsorbed model antigen [ovalbumin (OVA)] showed that a significantly larger fraction of the vaccine dose localized in the draining lymph nodes (dLNs) and the spleen 6 h after i.p. immunization, as compared to after i.m. immunization. Studies with fluorescently labelled OVA + CAF09 demonstrated a preferential association of OVA + CAF09 to DCs/monocytes, as compared to macrophages and B cells, following i.p. immunization. Administration of OVA + CAF09 via the i.p. route did also result in DC activation, whereas no DC activation could be measured within the same period with unadjuvanted OVA and OVA + CAF09 administered via the s.c. or i.m. routes. In the dLNs, the highest level of activated, cross-presenting CD8α+ DCs was detected at 24 h post immunization, whereas an influx of activated, migrating and cross-presenting CD103+ DCs to the dLNs could be measured after 48 h. This suggests that the CD8α+ DCs are activated by self-draining OVA + CAF09 in the lymphoid organs, whereas the CD103+ DCs are stimulated by the OVA + CAF09 at the SOI. These results support the hypothesis that the self-drainage of OVA + CAF09 to the draining LNs is required for the activation of CD8α+ DCs, while the migratory CD103+ DCs may play a role in sustaining the subsequent induction of strong CD8+ T-cell responses.

[1]  A. Brooks,et al.  Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.

[2]  Remo Guidieri Res , 1995, RES: Anthropology and Aesthetics.

[3]  P. Andersen,et al.  Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. , 2005, Biochimica et biophysica acta.

[4]  T. Allen,et al.  Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.

[5]  P. Andersen,et al.  A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells , 2009, PloS one.

[6]  Yvonne Perrie,et al.  Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  K. Murphy,et al.  Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells , 2010, The Journal of experimental medicine.

[8]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[9]  P. Andersen,et al.  High‐frequency vaccine‐induced CD8+ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection , 2014, European journal of immunology.

[10]  Sang-Ho Kim,et al.  Principles of , 2013 .

[11]  U. Yrlid,et al.  Lymph-borne CD 8 a þ dendritic cells are uniquely able to cross-prime CD 8 þ T cells with antigen acquired from intestinal epithelial cells , 2014 .

[12]  R. Johnston,et al.  Alphavirus-Adjuvanted Norovirus-Like Particle Vaccines: Heterologous, Humoral, and Mucosal Immune Responses Protect against Murine Norovirus Challenge , 2009, Journal of Virology.

[13]  Yvonne Perrie,et al.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.

[14]  D. Tough,et al.  Type I interferon as a stimulus for cross-priming. , 2008, Cytokine & growth factor reviews.

[15]  S. Dow,et al.  Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes1 , 2006, The Journal of Immunology.

[16]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[17]  P. Stayton,et al.  Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[19]  John J. Erickson,et al.  Human Metapneumovirus Virus-Like Particles Induce Protective B and T Cell Responses in a Mouse Model , 2014, Journal of Virology.

[20]  G. Belz,et al.  Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. M. Nielsen,et al.  Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[22]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[23]  J. Hubbell,et al.  Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. , 2013, Biomaterials.

[24]  L. Jorgensen,et al.  Protein Antigen Adsorption to the DDA/TDB Liposomal Adjuvant: Effect on Protein Structure, Stability, and Liposome Physicochemical Characteristics , 2012, Pharmaceutical Research.

[25]  A. Iwasaki,et al.  Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection , 2009, The Journal of experimental medicine.

[26]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[27]  F. Sánchez‐Madrid,et al.  CD69 is an immunoregulatory molecule induced following activation. , 2005, Trends in immunology.

[28]  Gabrielle T Belz,et al.  Dendritic cells: driving the differentiation programme of T cells in viral infections , 2008, Immunology and cell biology.

[29]  C. Kurts,et al.  Cross-priming in health and disease , 2010, Nature Reviews Immunology.

[30]  M. Swartz,et al.  The physiology of the lymphatic system. , 2001, Advanced drug delivery reviews.

[31]  D. Venzon,et al.  TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection , 2011, The Journal of Immunology.

[32]  G. Karupiah,et al.  Cutting Edge: Conventional CD8α+ Dendritic Cells Are Generally Involved in Priming CTL Immunity to Viruses 1 , 2004, The Journal of Immunology.

[33]  J. Ward,et al.  A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. , 2004, Vaccine.

[34]  R. Rappuoli,et al.  The Intangible Value of Vaccination , 2002, Science.

[35]  J. Ruberte,et al.  Lymphatic drainage of Listeria inonocytogenes and Indian ink inoculated in the peritoneal cavity of the mouse , 1992, Laboratory animals.

[36]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[37]  P. Andersen,et al.  Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. , 2014, Vaccine.

[38]  C. Foged,et al.  License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[40]  P. Andersen,et al.  CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice , 2012, Cancer Immunology, Immunotherapy.

[41]  F. Baneyx,et al.  Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[42]  H. M. Nielsen,et al.  Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo , 2011, Pharmaceutical Research.

[43]  R. Kroczek,et al.  Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells , 2014, Mucosal Immunology.

[44]  J. Buer,et al.  Immunization with Biodegradable Nanoparticles Efficiently Induces Cellular Immunity and Protects against Influenza Virus Infection , 2013, The Journal of Immunology.

[45]  J. Ramsey,et al.  The role of the lymphatic system in vaccine trafficking and immune response. , 2011, Advanced drug delivery reviews.

[46]  Nicholas Collins,et al.  Cutting Edge: CD69 Interference with Sphingosine-1-Phosphate Receptor Function Regulates Peripheral T Cell Retention , 2015, The Journal of Immunology.

[47]  F. Zepp Principles of vaccine design-Lessons from nature. , 2010, Vaccine.

[48]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[49]  G. Belz,et al.  Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.

[50]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[51]  H. M. Nielsen,et al.  Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.